07:00 , Jul 31, 2008 |  BC Innovations  |  Tools & Techniques

Look to the side (effects)

Researchers at the European Molecular Biology Laboratory have developed an approach for repurposing therapeutics that could eliminate a lot of the guesswork associated with current methods. Their work, published in Science , describes a systematic...
07:00 , Jul 25, 2005 |  BioCentury  |  Strategy

Global springboard

Sosei Co. Ltd. dramatically shifted its center of gravity out of Japan - broadening its pipeline, investor base, cash balance and geographic footprint - when it announced last week that it would acquire Arakis Ltd....
07:00 , Jun 27, 2005 |  BC Week In Review  |  Clinical News

SOU-001: Phase II start

Sosei will begin in the second half a placebo-controlled, U.K. Phase II trial in 24 female volunteers with SUI. Patients will receive single oral doses of SOU-001. The compound originally was developed up to Phase...
07:00 , Apr 18, 2005 |  BioCentury  |  Strategy

Reprofiler Profiles

Reprofiler Profiles Company Most advanced reprofiled compound (partner) Total compounds in clinic (not reprofiled) Total raised ($M) Last financing Raised ($M) Date Literature & database searches Arachnova Ph I 4 (A) ND (B) ND ND...
07:00 , Apr 18, 2005 |  BioCentury  |  Strategy

Reprofiler report card

Reprofiling companies' raison d'être is to get drugs to market faster and cheaper than conventional R&D companies by developing marketed or failed compounds for new applications. Most reprofiled compounds already have been shown to be...
08:00 , Mar 22, 2004 |  BC Week In Review  |  Company News

Arachnova Therapeutics Ltd., Mitsubishi Pharma deal

Arachnova received a license to develop Mitsubishi's MCI-225 , a noradrenaline and serotonin reuptake inhibitor, and serotonin (5-HT3) receptor antagonist, for pain, stress urinary incontinence and functional bowel disorder. Arachnova used its SwitchBase technology to...
08:00 , Mar 22, 2004 |  BioCentury  |  Strategy

Double dealing

Mitsubishi Pharma Corp. has now out-licensed the data package for its MCI-225 molecule twice, setting up what could be a patent battle somewhere down the road for the biotech companies that have licensed it. Both...
08:00 , Mar 1, 2004 |  BC Week In Review  |  Company News

Arachnova Therapeutics Ltd., Sosei Co. Ltd. deal

Sosei obtained exclusive worldwide rights from Arachnova to develop and market AA10020/SOU001 for stress urinary incontinence (SUI). Arachnova will receive an upfront license fee and is eligible for milestones and royalties. Under a previous deal,...
08:00 , Feb 25, 2004 |  BC Extra  |  Company News

Sosei, Arachnova licensing deal

Sosei (Tokyo, Japan) obtained exclusive worldwide rights from Arachnova (Cambridge, U.K.) to develop and market AA10020/SOU001 for stress urinary incontinence. Arachnova will receive an upfront license fee and is eligible for milestones and royalties. Under...